Technical Analysis for ANL - Adlai Nortye Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -1.13% | |
| Inside Day | Range Contraction | -1.13% | |
| 20 DMA Support | Bullish | -5.76% | |
| Inside Day | Range Contraction | -5.76% | |
| Gapped Down | Weakness | -5.76% | |
| Lower Bollinger Band Touch | Weakness | -5.76% | |
| Crossed Above 20 DMA | Bullish | -5.89% | |
| Gapped Down | Weakness | -5.89% | |
| Hammer Candlestick | Bullish | 0.77% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.77% |
| Alert | Time |
|---|---|
| Down 1% | about 2 hours ago |
| 20 DMA Support | 3 days ago |
| 10 DMA Support | 3 days ago |
| Down 5% | 3 days ago |
| Down 3% | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/28/2024
Adlai Nortye Ltd. Description
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Cancer Therapies Checkpoint Inhibitor Clusters Of Differentiation Tumor Microenvironment Programmed Cell Death Protein 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.2999 |
| 52 Week Low | 7.1114 |
| Average Volume | 9,433 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 11.23 |
| 20-Day Moving Average | 13.50 |
| 10-Day Moving Average | 13.28 |
| Average True Range | 1.35 |
| RSI (14) | 53.92 |
| ADX | 15.83 |
| +DI | 17.76 |
| -DI | 20.51 |
| Chandelier Exit (Long, 3 ATRs) | 11.51 |
| Chandelier Exit (Short, 3 ATRs) | 13.84 |
| Upper Bollinger Bands | 14.63 |
| Lower Bollinger Band | 12.37 |
| Percent B (%b) | 0.39 |
| BandWidth | 16.80 |
| MACD Line | 0.60 |
| MACD Signal Line | 0.74 |
| MACD Histogram | -0.1401 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.50 | ||||
| Resistance 3 (R3) | 14.55 | 14.19 | 14.29 | ||
| Resistance 2 (R2) | 14.19 | 13.87 | 14.16 | 14.22 | |
| Resistance 1 (R1) | 13.72 | 13.68 | 13.54 | 13.67 | 14.15 |
| Pivot Point | 13.36 | 13.36 | 13.27 | 13.33 | 13.36 |
| Support 1 (S1) | 12.89 | 13.04 | 12.71 | 12.84 | 12.35 |
| Support 2 (S2) | 12.53 | 12.85 | 12.50 | 12.28 | |
| Support 3 (S3) | 12.06 | 12.53 | 12.21 | ||
| Support 4 (S4) | 12.01 |
